ATRT-23. SMARCB1-DEPENDENCIES IN ATYPICAL TERATOID/RHABDOID TUMOURS: A STRATEGY FOR PRE-CLINICAL THERAPEUTIC TARGET IDENTIFICATION IN THE ABSENCE OF ACTIONABLE MUTATIONS

ATRTs have low mutation rates and few classically-actionable variants to direct molecularly targeted therapies; loss of SMARCB1 is the sole recurrent mutational event in >90% of ATRTs. We have designed and implemented a genome-scale strategy for target identification and prioritization in tumors...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Finetti, Martina Anna, Selby, Matthew p, Pons, Alicia del-Carpio, Batting, Sarah, Wood, James A, Barker, James M, Smith, Amanda, Crosier, Stephen, Bashton, Matthew, Pickles, Jessica C, Fairchild, Amy R, Avery, Aimee, O’Hare, Patricia, Pizer, Barry, Brennan, Bernadette, Lowis, Stephen, Hargrave, Darren, Jacques, Thomas S, Bailey, Simon, Clifford, Steven C, Williamson, Daniel
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012497/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.021
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items